Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Biotechnology
- Therapeutic
- Disease
- Pharmaceuticals
- Diagnostic
- Immune
- Antibody
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26921
IPSCIO Record ID: 29291
IPSCIO Record ID: 6797
The following patents and patent applications, together with the know-how related thereto, constitute the BR96 sFV-PE40 Program
Patent
 Â
Description
License Type
Number
Number
57,444
5,491,088
 Â
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive
459,354
 Â
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive
Table 2 BR96/Drug Conjugate Program
Application
Patent
 Â
Description
License Type
Number
Number
353,729
5,122,368
 Â
Linker chemistry having an acylhydrazone linkage through C13 keto group of anthracycline to nonimmunoglobulin ligand. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers
96,628
 Â
Acylhydrazone linkage through C13 keto group of anthracycline to immunoglobulin. Linker arm also includes thioether or disulfide bond.
Partially-Exclusive for Linkers
824,951
5,622,929
 Â
Anthrecycline ligand conjugates where linkage is an acylhydrazone through C13 keto position of anthracycline. Linker also contains succinimido moiety. Chemistry is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers
08/468,162
5,606,017
 Â
Anthracycline intermediate having acylhydrazone linkage through C13 keto position of anthracycline and a Michael Addition Receptor. Intermediate in conjugation used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers
08/469,840
 Â
Process for conjugation using intermediate above with reduced immunoglobulin to increase total drug to antibody yield. Process is used to make first generation chiBR96-Dox.
Partially-Exclusive for Linkers
62,366
 Â
Enzyme cleavable peptide linker for making cytotoxic drug ligand conjugates. Linkers are used to make second generation BR96-Dox.
Partially-Exclusive for Linkers
57,444
5,491,088
 Â
Murine monoclonal antibody BR96, chimeric BR96 and antigen binding fragments of BR96.
Exclusive
77,253
 Â
Immunoconjugates of murine monoclonal antibody BR96, chimeric BR96 and other recombinant antigen binding fragments. Includes single chain and bispecific recombinant constructs.
Exclusive
333,840
 Â
Methods of treating human carcinoma by administering murine BR96, chimeric BR96 or any recombinant antigen binding construct either by itself or conjugates with various agents. Also includes diagnostic kits.
Exclusive
459,354
 Â
Recombinant BR96 molecules having the antigen binding region of murine BR96.
Exclusive
08/285,936
 Â
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive
08/487,860
 Â
Mutants of BR96 which have increased binding affinity/avidity to antigen.
Exclusive
60/030/367
 Â
Branched peptide linker for linking thiol group on targeting ligand to two or more drug moieties.
Partially-Exclusive for Linkers
5,204,244
 Â
Production of chimeric antibodies by homologous recombination.
Non-Exclusive
5,202,238
 Â
Production of chimeric antibodies by homologous recombination.
Non-Exclusive
5,482,856
 Â
Production of chimeric antibodies by homologous recombination.
Non-Exclusive
Table 3 G28-5 SfV/Immunotixin Program
The patents and patent applications (the “Washington Patentsâ€), together with the know-how related thereto, sublicensed under the Washington Agreement constitute the G28-5 sFv/Immunotoxin Program. [Exclusive]
Table 4 BD1 Program
The following patents and patent applications, together with the know-how related thereto, constitute the BD1 Program
Application
Patent
Description
License Type
Number
Number
08/245,754
5,541,110
Isolated oligonucleotide sequence encoding Bryodin 1, recombinant vectors and plasmids, and transfected host cells.
Exclusive
08/597,731
Methods for the recombinant production of Bryodin 1 and Bryodin 1-ligand fusion proteins.
Exclusive
08/324,301
5,597,569
Ribosome-inactivating protein Bryodin 2 in an isolated form, linked to a ligand as a conjugate or a fusion protein, pharmaceutical compositions, nucleotide sequence, transfected host cells and recombinant production.
Exclusive
Table 5 ADEPT Program
The following patents and patent applications, together with the know-how related thereto, constitute the ADEPT Program
Application
Number
Patent
Description
License Type
(filed 5/7/96)
Number
Recombinant L49sFv-¨ lactamase fusion proteins which recognize p97 melanoma antigen and activate-cephalosporin derivatized prodrug molecules.
Exclusive
211,301
4,975,278
Methods for delivering cytotoxic agents to tumor cells by administering an effective amount of at least one antibody-enzyme conjugate, wherein the antibody is specific for a tumor associated antigen and the enzyme converts at least one weakly cytotoxic prodrug to its corresponding cytotoxic parental form; and the administration of an effective amount of the prodrug.
Non-Exclusive
Table 6 Residual Program
The following patents and patent applications, together with the know-how related thereto, constitute the Residual Program
Application
Patent
Description
License Type
Number
Number
684,759
4,935,495
Monoclonal antibodies, Fab, F(ab1)2 or Fv fragments thereof which compete for binding with L6 to its antigen.
Partially-Exclusive for Cancer
776,321
4,906,562
Methods for detecting malignancy using L6 or other monoclonal antibodies or fragments thereof which compete with L6 for binding to its antigen.
Exclusive
523,309
5,091,177
Method for reducing population of tumor cells using L6 or monoclonal antibodies which compete for binding with L6 to its antigen.
Exclusive
443,696
5,242,824
Monoclonal antibody BR64 and antigen binding fragments thereof.
Exclusive
08/726,528
Monoclonal antibodies and recombinant antigen binding molecules which recognize the G733-1 but not G733-2 antigen. Specifically BR110.
Partially-Exclusive for Cancer
527,227
5,165,922
Method of treating breast carcinoma in an unresponsive patient by first administering monoclonal antibody L6 followed by administration of a chemotherapeutic agent.
Exclusive
5,663,158
Method for treating vascular leak syndrome.
Non-Exclusive
The Residual Program also includes antibodies L6, L49, BR64, BR110, OV578.1 and OV569.1 [Exclusive]
The Field with respect to Licensed Technology for which Licensee is granted a right and license that is partially exclusive shall be
(i) if this Agreement indicates that such license is partially exclusive for linkers, all monoclonal antibody targeting applications; or (ii) if the agreement indicates that such license is partially exclusive for cancer, the treatment and diagnosis of cancer in humans. The Field with respect to Licensed Technology for which Licensee is granted a right and license that is non-exclusive shall be the treatment and diagnosis of cancer in humans. Notwithstanding the foregoing, the Field with respect to the G28-5 Licensed Technology shall be for the use of the antibody G28-5 fused with a toxin for the treatment of cancer in humans.
IPSCIO Record ID: 28704
The Licensee was granted the right to develop antibodies related to the Licensor's antibodies against GM-CSF.
Licensor has developed certain chimeric antibodies that bind and/or modulate granulocyte-macrophage colony-stimulating factor, and intellectual property related thereto.
W003068920 and the US patent application with serial number 10/365,123
IPSCIO Record ID: 1395
(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.
“Humanized Antibody(ies)†means the humanized form of the Murine Antibody.
“Licensed Product(s)†means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.
“Murine Antibody(ies)†means, subject to Section 2.01(b), the murine monoclonal antibody designated as “PRO 140†directed against the Target Antigen.
IPSCIO Record ID: 144995
The Diagnostic Product shall mean a diagnostic product, containing one or more Program Antibodies, for use in the in vivo detection of solid tumors in humans.
The Therapeutic Product shall mean the final dosage formulation of a product incorporating pharmaceutical compositions containing a Program Antibody for use in the treatment of solid tumors in humans, regardless of the route of administration. Each different chemical formulation of a Therapeutic Product containing the same one or more Program Antibodies but no additional antibodies, except different formulations for use in the treatment of the same indication in the Field by different routes of administration, shall constitute a different Therapeutic Product.
